To further validate the target-specificity of PolVed in sCD79b+ BCP-ALL cells, we compared the efficacy of PolVed to that of the CD30-ADC Brentuximab Vedotin (BreVed) in vivo in the E2A-PBX1+ sCD79b+/CD30– PDX model (Suppl. Here, TNFRSF8 is linked to acute lymphoblastic leukemia.